Ignite Creation Date:
2024-05-06 @ 1:54 PM
Last Modification Date:
2024-10-26 @ 1:21 PM
Study NCT ID:
NCT04155580
Status:
TERMINATED
Last Update Posted:
2023-02-21
First Post:
2019-11-05
Brief Title:
A Study of ASTX660 as a Single Agent and in Combination With ASTX727 in Subjects With RelapsedRefractory Acute Myeloid Leukemia AML
Sponsor:
Astex Pharmaceuticals Inc
Organization:
Astex Pharmaceuticals Inc
Conditions & Keywords Data
Conditions:
| Name |
|---|
| Acute Myeloid Leukemia |
Keywords:
| Name | View |
|---|---|
| AML | View |
| Bone marrow | View |
| CMML | View |
| MDS | View |
| ASTX727 | View |
| ASTX660 | View |
| cIAP1 | View |
| Cellular inhibitor of apoptosis protein | View |
| XIAP | View |
| CDAi | View |
| Cytidine deaminase inhibitor | View |
| Cedazuridine | View |
| Decitabine | View |
| Acute myeloid leukemia | View |
| Chronic myelomonocytic leukemia | View |
| Myelodysplastic syndrome | View |